RecruitingNot ApplicableNCT04110522

Psoriatic Arthritis D2P Screening

Accelerating Psoriatic Arthritis Detection in Patients With Psoriasis: Direct-to-patient Administration of Screening Questionnaires (D2P Screening)


Sponsor

Jessica Walsh

Enrollment

18,000 participants

Start Date

Jul 22, 2019

Study Type

INTERVENTIONAL

Conditions

Summary

The overarching goal of this study is to develop a direct-to-patient screening approach that will improve early Psoriatic Arthritis (PsA) detection in patients with psoriasis. Previously developed screening questionnaires were intended for use in the setting of a doctor's office to assist providers with referral decisions. However, these screening questionnaires are infrequently used in routine practice because of limitations with time and resources. The study will aim to develop a practical screening strategy that does not require involvement from dermatologists (or other non-rheumatology providers) and can systematically reach a broad range of psoriasis patients, including patients not attending dermatology clinics. The researchers hypothesize that disseminating questionnaires directly to patients outside of a clinic setting (direct-to-patient approach) will educate patients about their PsA risk and improve early PsA diagnoses.


Eligibility

Min Age: 18 Years

Inclusion Criteria3

  • Have an International Classification of Diseases (ICD) code diagnosis of psoriasis but without a confirmed diagnosis of Psoriatic Arthritis prior to study initiation
  • Be age 18 or older
  • Be geographically located within a reasonable proximity to the Rheumatology study site

Exclusion Criteria1

  • Have psoriasis and a confirmed diagnosis of psoriatic arthritis made or confirmed by a rheumatologist

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

OTHERDirect to patient PsA Screening Questionnaire

Patients randomized to an intervention group will be asked to complete and score the 5-item Psoriasis Epidemiology Screening Tool (PEST) questionnaire. Those patients with an elevated score (PEST ≥3 out of 5) will be advised to complete a rheumatologic evaluation for PsA.


Locations(2)

University of Pennsylvania

Philadelphia, Pennsylvania, United States

University of Utah

Salt Lake City, Utah, United States

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT04110522


Related Trials